Ann Dermatol.  2010 May;22(2):170-172. 10.5021/ad.2010.22.2.170.

Cyclosporin Treatment of Atopic Dermatitis: Is It Really Associated with Infectious Diseases?

• Kim SW
• Park YW
• Kwon IH
• Kim KH

• KMID: 2265387
• DOI: http://doi.org/10.5021/ad.2010.22.2.170

Abstract

BACKGROUND
Patients with severe atopic dermatitis (AD) can benefit from cyclosporin (CSA) treatment. Some studies reported that CSA can cause infectious diseases as side effects.
OBJECTIVE
To investigate the possible association of CSA treatment in AD patients with infectious diseases.
METHODS
We performed a case-controled study on 202 patients with AD, 101 of whom were taking CSA and 101 who were not. Retrospective medical record review was held, and the incidence of infectious disease in both groups was compared. RESULTS: The total number of infectious diseases in the CSA group was slightly lower than in control group but that was not statistically significant. Similarly, the incidence density was almost the same in the two groups. In both groups, eczema herpeticum was the most common infection.
CONCLUSION
Our results suggest that CSA therapy in AD does not increase the incidence of infectious disease.

Keyword

Atopic dermatitis; Cyclosporin; Infectious disease

MeSH Terms

Case-Control Studies
Communicable Diseases
Cyclosporine
Dermatitis, Atopic
Humans
Incidence
Kaposi Varicelliform Eruption
Medical Records
Retrospective Studies
Cyclosporine

Reference

1. Chan LS. Atopic dermatitis in 2008. Curr Dir Autoimmun. 2008. 10:76–118.

2. Bunikowski R, Staab D, Kussebi F, Brautigam M, Weidinger G, Renz H, et al. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. Pediatr Allergy Immunol. 2001. 12:216–223.

3. Czech W, Brautigam M, Weidinger G, Schopf E. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol. 2000. 42:653–659.

4. van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol. 1994. 130:634–640.

5. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000. 4:1–191.

6. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007. 21:606–619.

7. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000. 142:52–58.

8. Atakan N, Erdem C. The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis. J Eur Acad Dermatol Venereol. 1998. 11:240–246.

9. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol. 1997. 136:76–81.